Last reviewed · How we verify
NCT06279624
Effectiveness of the PCV13 in Older Thai Adults
trial in Community-acquired Pneumonia in 825 participants. Completed in 30 January 2025.
30 January 2025
Quick facts
| Lead sponsor | Mahidol University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 825 |
| Start date | 5 February 2024 |
| Primary completion | 30 January 2025 |
| Estimated completion | 30 January 2025 |
| Sites | 1 location across Thailand |
Conditions studied
- Community-acquired Pneumonia — all drugs for Community-acquired Pneumonia →
Sponsor
Mahidol University
Who can join
60 and older, any sex, with Community-acquired Pneumonia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is the matched 1:2 case-control study, prospectively collect case and control who are diagnosed with pneumococcal or non-pneumococcal community acquired pneumonia (CAP), accordingly from November 2023 through October 2024. The investigators define a CASE as a person aged ≥60 years due to pneumococcal confirmed CAP either in-patients or out-patients by doctor in charge. While a CONTROL is defined as a person aged ≥60 years due to non-pneumococcal confirmed CAP either in-patients or out-patients by doctor in charge. The goal of this observational study is to evaluate the effectiveness of the 13-valent pneumococcal conjugate vaccine (PCV13) in pneumococcal CAP in Thai adults aged ≥ 60 years with or without any medical conditions. The main questions it aims to answer is: • What are the effectiveness of PCV13 for preventing all typed, vaccine typed, or non-vaccine typed of pneumococcal CAP among Thai older adults? The investigators retrospectively collect cases and control who are diagnosed with CAP accordingly from January 2012 through October 2023. The investigators define case and control the same as prospective method, but all data were retrieved from archive database. -The investigators select a 1:2 matched control with criteria as follows; 10-year-interval of age, ward (the same patient care such as out or in-patient, or admitted in the same level ward). Participants will be * collated from hospital database regarding their CAP illnesses by pneumococcal and non-pneumococcal pneumonia condition. * explored their vaccine status by either vaccine book checking or hospital database. Researcher will compare the effectiveness of PCV13 to prevent all typed, vaccine typed and non-vaccine typed pneumococcal pneumonia.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effectiveness of the 13-valent pneumococcal conjugate vaccine against medically attended pneumococcal lower respiratory tract infection among older adults: a case-control study.
Ngamprasertchai T, Phatharodom P, Intalapaporn K, Sutthipool K, et al · · 2025 · cited 1× · PMID 41266522 · DOI 10.1038/s41598-025-24784-0
Verify or expand the search:
- PubMed search for NCT06279624
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Community-acquired Pneumonia
Currently open trials in the same condition.
- NCT07164131 — Azithromycin Versus Doxycycline in Hospitalized Adult Patients With Community Acquired Pneumonia Treated With Beta-lacta · Phase 4 · recruiting
- NCT06577558 — Efficacy and Safety of SR1375 in Adult Patients With CAP · Phase 2 · recruiting
- NCT06229288 — Amoxicillin Alone Versus Amoxicillin/Clavulanate for Community-acquired Pneumonia in Patients Aged 65 Years or Older, an · Phase 3 · recruiting
- NCT06125340 — Optimizing Care for Children Hospitalized With Community-acquired Pneumonia: Short-course Therapy · Phase 4 · recruiting
- NCT06114888 — Optimizing Care for Children Hospitalized With Community-acquired Pneumonia: Novel Diagnostics · NA · recruiting
Other Mahidol University trials
Trials by the same sponsor.
- NCT07568496 — Greater Occipital Nerve Block for Migraine With Medication Overuse Headache · NA · not yet recruiting
- NCT07407400 — Lemborexant for Sleep and Delirium Prevention in Elderly ICU Patients · Phase 4 · not yet recruiting
- NCT07378501 — Thai Version of the Pediatric Quality of Recovery Score (PedSQoR): Translation and Psychometric Validation Study · not yet recruiting
- NCT07438301 — Septic Shock Hemodynamic Respond to Volume Resuscitation Versus Vasopressor Administration · not yet recruiting
- NCT07390006 — Enabling Patient-Reported Outcomes Through Innovative Care - ACS (EPIC-ACS) · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06279624 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mahidol University
- Last refreshed: 9 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06279624.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing